Date: October 07, 2021
Time: 10:00am (PDT), 1:00pm (EDT)
It's estimated than less than 10% of investigational anti-cancer drugs successfully achieve FDA approval for clinical use. This is often attributed to the fact that it’s difficult to identify patients whose tumors are most likely to respond to a specific treatment. Patient derived xenografts (PDXs) are bringing new hope when it comes to this challenging task, yet finding the ideal animal model to grow the PDX tumors to test new therapies can be challenging. The new B-NDG mouse model is our newest triple immunodeficient mouse with proven performance in cancer and immuno-oncology research. Join this webinar to learn more about the model and how the B-NDG compares to existing models like the JAX® NSG™ mice in CDX and PDX tumor studies.
- Review B-NDG model development, characteristics, and research uses
- Compare differences between B-NDG and JAX® NSG™ mice
- Examine growth of B-NDG vs NSG™ models in CDX tumor studies
- Evaluate performance of B-NDG vs NSG™ models in PDX tumor studies
JAX® is a registered trademark and NSG™ is a trademark of The Jackson Laboratory.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.